Postpartum Depression Market Report 2026

The postpartum depression market size has grown exponentially in recent years. It will grow from $16.05 billion in 2025 to $21.17 billion in 2026 at a compound annual growth rate (CAGR) of 31.9%. The growth in the historic period can be attributed to increasing recognition of maternal mental health disorders, limited early screening practices, underdiagnosis in postpartum care settings, reliance on traditional counseling approaches, growing hospital-based maternal care services.

The postpartum depression market size is expected to see exponential growth in the next few years. It will grow to $66.48 billion in 2030 at a compound annual growth rate (CAGR) of 33.1%. The growth in the forecast period can be attributed to increasing adoption of digital screening tools, rising focus on preventive maternal healthcare, expansion of tele-mental health services, growing investment in women’s mental health programs, increasing integration of mental health into obstetric care. Major trends in the forecast period include increasing awareness and screening for postpartum mental health, growing acceptance of digital mental health platforms, rising focus on early diagnosis and intervention, expansion of community-based support programs, enhanced integration of mental health services in maternal care.

The increasing number of childbirths is expected to drive the growth of the postpartum depression market. Childbirth refers to the process through which a baby is delivered from the mother’s uterus, most commonly via the vaginal canal. The rise in childbirths contributes to the expansion of the postpartum depression market because postpartum depression is a prevalent mental health condition that can affect women following delivery. It can lead to a broad range of symptoms, including sadness, anxiety, exhaustion, and difficulties in bonding with the newborn. For instance, in January 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health organization, the United States recorded a 1% increase in registered births, reaching 3,664,292 compared to the previous year. Therefore, the growing number of childbirths is fueling the growth of the postpartum depression market.

Major companies operating in the postpartum depression market are focusing on innovative product development, including achieving regulatory milestones to support the advancement and potential approval of zuranolone for major depressive disorder and postpartum depression. A regulatory milestone is a key event in the lifecycle of a drug or medical product that signifies progress within the approval or compliance framework established by regulatory authorities. For instance, in February 2023, Biogen Inc., a US-based biotechnology company, and Sage Therapeutics Inc., a US-based biopharmaceutical company, announced that the US Food and Drug Administration had accepted the filing of a new drug application for zuranolone for the treatment of major depressive disorder and postpartum depression. Zuranolone is an investigational medication being evaluated as a rapid-acting, once-daily oral therapy administered over 14 days for individuals with MDD and PPD. As a neuroactive steroid, zuranolone functions as a positive allosteric modulator of GABA-A receptors, representing a distinctive mechanism of action. It is intended to work by rapidly resetting dysregulated neural networks to help restore normal brain function. Zuranolone influences brain networks responsible for mood, arousal, behavior, and cognitive processes.

In July 2025, Supernus Pharmaceuticals, Inc., a US-based biopharmaceutical company focused on developing treatments for neuropsychiatric conditions, completed the acquisition of Sage Therapeutics, Inc. for an undisclosed amount. This acquisition allows Supernus to broaden its portfolio with ZURZUVAE (zuranolone), an FDA-approved oral therapy for postpartum depression, and to utilize Sage’s innovative central nervous system discovery platform to support mid- to long-term revenue growth. Sage Therapeutics, Inc. is a US-based company that develops therapies for neurological and neuropsychiatric disorders, including depression, postpartum depression, and other mental health conditions.

Major companies operating in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals plc, Sage Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Lundbeck A S, Janssen Pharmaceuticals, Aurobindo Pharma Ltd.

North America was the largest region in the postpartum depression market in 2025. The regions covered in the postpartum depression market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the postpartum depression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are moderately impacting the postpartum depression market by increasing costs associated with imported diagnostic tools, digital health platforms, pharmaceutical inputs, and medical devices used in maternal mental health screening and monitoring. Healthcare providers in North America and Europe are most affected due to dependence on imported medical technologies, while Asia-Pacific faces pricing pressure on digital health infrastructure. These tariffs contribute to higher operational costs for hospitals and clinics and can slow technology adoption. However, they are also encouraging local development of mental health solutions, regional manufacturing of medical devices, and increased investment in domestic digital healthcare platforms.

The postpartum depression market research report is one of a series of new reports that provides postpartum depression market statistics, including postpartum depression industry global market size, regional shares, competitors with a postpartum depression market share, detailed postpartum depression market segments, market trends and opportunities, and any further data you may need to thrive in the postpartum depression industry. This postpartum depression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Postpartum depression (PPD) is a mood disorder that affects some women after childbirth and may remain undiagnosed for extended periods. It is characterized by persistent feelings of sadness, hopelessness, and a reduced interest or pleasure in activities that were previously enjoyed.

The primary forms of postpartum depression include postpartum blues, postpartum anxiety, postpartum obsessive-compulsive disorder, postpartum panic disorder, postpartum post-traumatic stress disorder, postpartum psychosis, and others. Postpartum blues is a common and self-limiting condition that typically occurs soon after delivery and may present with symptoms such as mood fluctuations, irritability, and tearfulness. These conditions are managed through various treatment approaches including psychotherapy, medications, supplements, and others. Treatments are administered through multiple routes such as oral, parenteral, and others, and are distributed via channels including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a range of end users such as hospitals, specialty clinics, home-care settings, and others.

The postpartum depression market consists of revenues earned by entities by providing services such as medications, psychotherapy (cognitive behavioral therapy) and support group participation. The market value includes the value of related goods sold by the service provider or included within the service offering. The postpartum depression market also includes the sales of medications such as Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), Bupropion and Tricyclic antidepressants (TCAs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.